WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--
Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum as follows:
Date: September 23, 2026
Time: 1:30 PM ET
The presentation will provide a detailed look at the Company’s atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and emerging findings across distinct patient populations. These include patients with moderate-severe baseline pruritus, as well as a clinically important cohort characterized by lower EASI scores despite high investigator-assessed disease severity (IGA).
A live webcast of the presentation may be accessed on the Investors section of the Turn Therapeutics website at https://ir.turntherapeutics.com/news-events/events. A replay of the webcast will be available on the Turn Therapeutics website for approximately six months following the presentation.
About Turn Therapeutics
Turn Therapeutics Inc. is a clinical-stage biotechnology company developing targeted, non-systemic therapies designed to act directly at the site of disease. The Company’s lead therapeutic candidate, GX-03, is being evaluated in atopic dermatitis and is also being developed for onychomycosis. Turn’s research focuses on the intersection of microbial activity, local immune signaling and chronic inflammation.
A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.
pruritusmedical
Pruritus is the medical term for an unpleasant itch sensation that makes a person want to scratch, ranging from mild irritation to severe, persistent discomfort like an itch you can’t stop rubbing. For investors, it matters because it can be a key symptom or side effect in clinical trials, affect drug labeling and regulatory decisions, drive market demand for treatments, and signal safety or tolerability issues that influence a healthcare product’s commercial prospects.
easimedical
Eczema Area and Severity Index (EASI) is a standardized clinical score used to measure the extent and intensity of atopic dermatitis (eczema) on a patient’s body, combining how much skin is affected and how severe symptoms like redness and thickness are. For investors, EASI matters because it is often a primary endpoint in dermatology drug trials: larger or faster improvements in EASI can increase the chance of regulatory approval and commercial success, much like a clear test score can boost confidence in a new product.
igamedical
IgA (immunoglobulin A) is an antibody that acts like a first-line security guard on the body's surfaces—such as the gut, respiratory tract and eyes—helping block infections and clear harmful substances. For investors, IgA matters because it is a target and a biomarker in diagnostics and drug development for infections, autoimmune conditions and some kidney diseases; changes in IgA levels can influence clinical trial outcomes, regulatory decisions and market demand for treatments and tests.
